表紙
市場調查報告書
商品編碼
1042335

前列腺癌症診斷的全球市場 (2021年∼2028年)

Global Prostate Cancer Diagnostics Market - 2021-2028

出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 約2個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

  • 全貌
  • 簡介
  • 目錄
簡介

全球前列腺癌症診斷的市場規模在預測期間內 (2021年∼2028年) 預計將以13.2%高年複合成長率增長。市場主要促進因素有前列腺癌症診斷的持續性進步等。

在預測期內,按測試類型劃分的前列腺特異性抗原 (PSA) 檢測市場和按地區劃分的北美市場預計將以高複合年增長率增長。

本報告提供全球前列腺癌症診斷的市場相關分析,提供市場基本結構和主要的促進·阻礙因素,各檢驗類型·各終端用戶及各地區的市場趨勢預測,主要企業的簡介等相關調查。

目錄

第1章 前列腺癌症診斷市場:分析方法·範圍

第2章 前列腺癌症診斷市場:市場定義和概要

第3章 前列腺癌症診斷市場:摘要整理

第4章 前列腺癌症診斷市場:市場動態

  • 對市場的影響要素
    • 促進因素
    • 阻礙因素
    • 市場機會
    • 影響分析

第5章 前列腺癌症診斷市場:產業的要素

  • 波特的五力分析
  • 法規分析
  • 供應鏈分析
  • 價格分析
  • 技術的進步

第6章 前列腺癌症診斷市場:各檢驗類型

  • 簡介
    • 市場規模的分析與與前一年同期相比成長率 (%):各檢驗類型
    • 市場魅力指數:各檢驗類型
  • 攝護腺特異性抗原(PSA)檢驗
    • 簡介
    • 市場規模分析 (金額,2018年∼2026年)·與前一年同期相比成長率 (%) (2020年∼2028年)
  • 直腸手指診斷 (DRE)
  • 經直腸的超音波
  • PCA3檢驗
  • 影像診斷
  • 組織切片檢查
  • 其他

第7章 前列腺癌症診斷市場:各終端用戶

  • 簡介
  • 醫院·診所
  • 癌症研究所
  • 診斷中心
  • 其他

第8章 前列腺癌症診斷市場:各地區

  • 簡介
  • 北美
    • 簡介
    • 地區市場固有趨勢
    • 市場規模·與前一年同期相比成長率 (%):各檢驗類型
    • 市場規模·與前一年同期相比成長率 (%):各終端用戶
    • 市場規模·與前一年同期相比成長率 (%):各國
  • 南美
  • 歐洲
  • 亞太地區
  • 中東·非洲

第9章 前列腺癌症診斷市場:競爭情形

  • 競爭方案
  • 其他競爭公司的策略分析
  • 組合的種類:比較分析
  • 市場定位/佔有率分析
  • 企業合併·收購 (M&A) 的分析

第10章 前列腺癌症診斷市場:企業簡介

  • Genomic Health, Inc.
    • 企業概要
    • 產品的組合·概要
    • 主要的焦點
    • 財務概要
  • Quanterix Corporation
  • Metamark Genetics
  • Myriad Genetics, Inc.
  • MDx Health
  • Siemens Healthcare GmbH
  • F. Hoffman-La Roche AG
  • OPKO Health, Inc.

第11章 前列腺癌症診斷市場:DataM

目錄
Product Code: DM2247

Global Prostate Cancer Diagnostics Market is segmented By Test Type (Prostate-specific antigen (PSA) Test, Digital rectal exam (DRE), Transrectal Ultrasound, PCA3Test, Diagnostic Imaging, Tissue Biopsy, Others), By End-User (Hospitals & Clinics, Cancer Research Institutes, Diagnostic Centers, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Share, Size, Outlook, and Opportunity Analysis, 2021-2028.

Market Overview

The Global Prostate Cancer Diagnostics Market is expected to grow at a high CAGR of 13.2% during the forecasting period (2021-2028).

Prostate cancer begins when cells in the prostate gland start to grow out of control. The prostate is a gland found only in males. It makes some of the fluid that is part of semen.

Almost all prostate cancers are adenocarcinomas. These cancers develop from the gland cells (the cells that make the prostate fluid added to the semen). Some other types of cancer that can start in the prostate include small cell carcinomas, neuroendocrine tumors, transitional cell carcinomas, and sarcomas. Prostate cancer can often be found early by testing prostate-specific antigen (PSA) levels in a man's blood or digital rectal exam (DRE). According to a study in the United States, the annual screening with PSA and DRE did detect more prostate cancers than in men not screened, but this screening did not lower prostate cancer's death rate.

Market Growth

The continuous advancements in diagnostic for prostate cancer are driving the growth of the market globally. Some of the new test-launched by major players are:

On December 29th, 2019, Anixa Biosciences, Inc. commercially launched the Cchek Prostate Cancer Confirmation test (Cchek PCC)- which utilizes artificial intelligence (AI), flow cytometry, and liquid-biopsy technology to detect prostate cancer was commercially launched. Once it becomes available, this test will reduce the need for expensive and invasive biopsy procedures to diagnose prostate cancer patients in certain patients.

In September 2019, a new and simple blood test was found to efficiently and accurately detect the presence of aggressive prostate cancer, according to research by Queen Mary University of London. In combination with the current prostate-specific antigen (PSA) test, the new test could help men avoid unnecessary and invasive biopsies, over-diagnosis and over-treatment. The new prostate cancer test (the Parsortix® system from ANGLE plc) detects early cancer cells or circulating tumor cells (CTCs) that have left the original tumor and entered the bloodstream before spreading around the body. In July 2019, MDNA Life Sciences launched the Mitomic® Prostate Test (MPTTM), the world's most accurate blood test, to determine whether a man does or does not have prostate cancer that requires treatment (clinically significant prostate cancer1).

The Prostate-Specific Antigen (PSA) Test Market is expected to grow at a high CAGR during the forecasting period (2020-2027).

Prostate-specific Antigen (PSA) is a protein produced by prostate cells, and the PSA test is performed to diagnose prostate cancer (PCa) in men and for follow-up post-treatment to check if cancer relapses. PSA testing is an essential tool for detecting prostate cancer, which measures PSA's level in a man's blood. Medicare and several private insurers provide coverage for an annual PSA test for all Medicare-eligible men aged 50 and older. PSA testing is gaining popularity among clinicians and hospitals, owing to the increasing number of people affected by prostate cancer. It has more market value in the countries with a high prevalence rate (Western) and low prevalence rate (Asian), as PSA is used globally for the early detection/screening of prostate cancer. The major players continuously innovate new PSA with advanced technology, which boosts the PSA test's growth in the prostate cancer diagnosis market. For instance, in February 2019, OPKO Health, Inc. received the U.S. Food and Drug Administration (FDA) approval for the point-of-care Sangia Total Prostate Specific Antigen (PSA) Test using the Claros 1 Analyzer. The product is indicated to quantitatively measure total PSA in whole blood from a fingerstick of blood collected by a healthcare professional. It is used in conjunction with a digital rectal exam to detect prostate cancer in men aged 50 years and older.

Geographical Analysis

North America's prostate cancer diagnostics market is expected to grow at a high CAGR during the forecasting period (2020-2027).

North America is dominating the global prostate cancer diagnostics market, with the United States accounting as the major contributor to the market. Prostate cancer is one of the most common cancers in American men, and this is made apparent by the statistics surrounding it. It is estimated by the American Cancer Society that in 2019 there will be about 174,650 men with newly diagnosed prostate cancer, which is a 6% increase from 2018. There will also be an estimated 31,620 deaths from prostate cancer in 2019, a 7% increase from 2018. According to Zero Cancer, every 17 minutes, another man in the U.S. dies from prostate cancer, which is about 86 deaths per day. The number of deaths increases year after year, making prostate cancer the second leading cause of cancer death in men in the United States. Hence, it is considered to have an early diagnosis of the condition. The United States Preventive Services Task Force has analyzed the data from all reported prostate cancer screening trials, principally from the PLCO and ERSPC trials, and estimated that every 1,000 men ages 55 to 69 years screened every 1 to 4 years for 10 to 15 year. About 1 death from prostate cancer can be avoided. 120 men would have a false-positive test result that leads to a biopsy, and some men who get a biopsy would experience at least moderately bothersome symptoms from the biopsy. 100 men would be diagnosed with prostate cancer. Of those, 80 would be treated (either immediately or after a period of active surveillance) with surgery or radiation. At least 60 of these men would have a serious complication from treatment, such as erectile dysfunction and/or urinary incontinence.

Market Key Players

The growing awareness towards the availability of advanced cancer diagnostics technologies, especially in the emerging regions, is also likely to grow the prostate cancer diagnostics market. In addition to this, various governments' supportive initiatives across the globe would help boost the market growth.

Some of the major players dominating the market include: Genomic Health, Inc., Quanterix Corporation, Metamark Genetics, Myriad Genetics, Inc., MDx Health, Siemens Healthcare GmbH, F. Hoffman-La Roche AG, OPKO Health, Inc., among others.

The key players are adopting several strategies such as product launches, partnerships, mergers and acquisitions, collaborations, finding a new market in their core competency to stay competitive in the market.

For instance,

In June 2019, OPKO Health, Inc. (had submitted a de novo request to the U.S. Food and Drug Administration (FDA) seeking regulatory clearance for the 4Kscore® test. The 4Kscore® test is a blood test used by health care professionals to assess a patient's risk of having aggressive prostate cancer after an abnormal prostate-specific antigen (PSA) test result and before a decision is made to perform a biopsy.

In July 2019, MDNA Life Sciences launched the Mitomic Prostate Test (MPT) in the UK, the world's most accurate blood test to determine whether a man does or does not have prostate cancer that requires treatment.

Why Purchase the Report?

  • Visualize the Prostate Cancer Diagnostics Market's composition across each indication regarding type and treatment options, highlighting the vital commercial assets and players.
  • Identify business opportunities in the Prostate Cancer Diagnostics Market by analyzing trends and co-development deals.
  • Excel data sheet with thousands of data points of the Prostate Cancer Diagnostics Market - level 4/5 segmentation.
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • Product mapping in excel for the principal products of all major market players

Target Audience

  • Equipment Suppliers/ Buyers
  • Service Providers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturers
  • Related Topic's
  • Cervical Cancer Diagnostics Market
  • Breast Cancer Diagnostics Market

Table of Contents

1. Prostate Cancer Diagnostics Market Methodology and Scope

  • 1.1. Research methodology
  • 1.2. Scope of the Report

2. Prostate Cancer Diagnostics Market Definition and Overview

3. Prostate Cancer Diagnostics Market - Executive Summary

  • 3.1. Market Snippet by Test Type
  • 3.2. Market Snippet by End-User
  • 3.3. Market Snippet by Region

4. Prostate Cancer Diagnostics Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing advancements in diagnostic tests
      • 4.1.1.2. Rising government initiatives for cancer awareness
    • 4.1.2. Restraints
      • 4.1.2.1. High cost associated with diagnostic procedures
    • 4.1.3. Opportunities
    • 4.1.4. Impact Analysis

5. Prostate Cancer Diagnostics Market - Industry Factors

  • 5.1. Porter's Five Forces
  • 5.2. Regulatory Analysis
  • 5.3. Supply Chain Analysis
  • 5.4. Pricing Analysis
  • 5.5. Technology Advancements

6. Prostate Cancer Diagnostics Market - By Test Type

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
    • 6.1.2. Market Attractiveness Index, By Test Type
  • 6.2. Prostate-specific antigen (PSA) Test*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis, US$ Million, 2018-2026 and Y-o-Y Growth Analysis (%), 2020-2028
  • 6.3. Digital rectal exam (DRE)
  • 6.4. Transrectal Ultrasound
  • 6.5. PCA3Test
  • 6.6. Diagnostic Imaging
  • 6.7. Tissue Biopsy
  • 6.8. Others

7. Prostate Cancer Diagnostics Market - By End-User

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 7.1.2. Market Attractiveness Index, By End-User
  • 7.2. Hospitals & Clinics*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2018-2026 and Y-o-Y Growth Analysis (%), 2020-2028
  • 7.3. Cancer Research Institutes
  • 7.4. Diagnostic Centers
  • 7.5. Others

8. Prostate Cancer Diagnostics Market - By Region

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
    • 8.1.2. Market Attractiveness Index, By Region
  • 8.2. North America
    • 8.2.1. Introduction
    • 8.2.2. Key Region-Specific Dynamics
    • 8.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
    • 8.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 8.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 8.2.5.1. U.S.
      • 8.2.5.2. Canada
      • 8.2.5.3. Mexico
  • 8.3. South America
    • 8.3.1. Introduction
    • 8.3.2. Key Region-Specific Dynamics
    • 8.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
    • 8.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 8.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 8.3.5.1. Brazil
      • 8.3.5.2. Argentina
      • 8.3.5.3. Rest of South America
  • 8.4. Europe
    • 8.4.1. Introduction
    • 8.4.2. Key Region-Specific Dynamics
    • 8.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
    • 8.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 8.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 8.4.5.1. Germany
      • 8.4.5.2. The U.K.
      • 8.4.5.3. France
      • 8.4.5.4. Spain
      • 8.4.5.5. Italy
      • 8.4.5.6. Rest of Europe
  • 8.5. Asia-Pacific
    • 8.5.1. Introduction
    • 8.5.2. Key Region-Specific Dynamics
    • 8.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
    • 8.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 8.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 8.5.5.1. China
      • 8.5.5.2. India
      • 8.5.5.3. Japan
      • 8.5.5.4. Australia
      • 8.5.5.5. Rest of Asia-Pacific
  • 8.6. Middle East & Africa
    • 8.6.1. Introduction
    • 8.6.2. Key Region-Specific Dynamics
    • 8.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
    • 8.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User

9. Prostate Cancer Diagnostics Market - Competitive Landscape

  • 9.1. Competitive Scenario
  • 9.2. Competitor Strategy Analysis
  • 9.3. Comparative Product Portfolio Analysis
  • 9.4. Market Positioning/Share Analysis
  • 9.5. Mergers and Acquisitions Analysis

10. Prostate Cancer Diagnostics Market - Company Profiles

  • 10.1. Genomic Health, Inc.
    • 10.1.1. Company Overview
    • 10.1.2. Product Portfolio and Description
    • 10.1.3. Key Highlights
    • 10.1.4. Financial Overview
  • 10.2. Quanterix Corporation
  • 10.3. Metamark Genetics
  • 10.4. Myriad Genetics, Inc.
  • 10.5. MDx Health
  • 10.6. Siemens Healthcare GmbH
  • 10.7. F. Hoffman-La Roche AG
  • 10.8. OPKO Health, Inc.

11. Prostate Cancer Diagnostics Market - DataM

  • 11.1. Appendix
  • 11.2. About Us and Services
  • 11.3. Contact Us